---
id: 116
title: Influenza Virus Diagnosis and Treatment
category: organisms
subcategory: viruses
tags: [influenza, oseltamivir, zanamivir, baloxavir, neuraminidase-inhibitors]
difficulty: medium
---

## Question

How is influenza diagnosed and treated? Use the **"Oseltamivir Within 48h (Ideally), Don't Wait for Testing if Severe"** framework.

## Answer

### **Influenza Types:**

- **Influenza A:** Most common, **seasonal epidemics**, **pandemic potential** (antigenic shift)
- **Influenza B:** Seasonal epidemics, **milder** than A
- **Influenza C:** Rare, mild illness

### **Diagnosis:**

| Test | Sensitivity | Turnaround Time | Use |
|------|-------------|-----------------|-----|
| **Rapid antigen detection (RIDT)** | **50-70%** | 15-30 min | **Low sensitivity** (negative does NOT rule out) |
| **PCR (molecular)** | **95-100%** | 1-6 hours | **Gold standard**, highly sensitive |
| **Viral culture** | High | 3-10 days | **Too slow** for clinical decisions |

### **Treatment:**

**Neuraminidase Inhibitors (First-Line):**

| Drug | Dosing | Route | Notes |
|------|--------|-------|-------|
| **Oseltamivir** (Tamiflu) | **75mg PO BID × 5 days** | **Oral** | **Most commonly used**, **preferred** |
| **Zanamivir** (Relenza) | 10mg inhaled BID × 5 days | **Inhaled** | Avoid in asthma/COPD (bronchospasm risk) |
| **Peramivir** (Rapivab) | 600mg IV × 1 | **IV** | Single-dose, for patients unable to take PO |

**Other Antivirals:**
- **Baloxavir marboxil** (Xofluza): 40mg PO × 1 dose (or 80mg if >80kg) - **Single-dose**, newer agent, **cap-dependent endonuclease inhibitor**

### **When to Treat:**

**Indications for Antiviral Treatment:**
- **Severe illness** (hospitalized, pneumonia, hypoxia)
- **High-risk patients:**
  - Age <2 years or >65 years
  - Pregnancy (any trimester) or <2 weeks post-partum
  - Chronic medical conditions (asthma, COPD, heart disease, diabetes, immunosuppressed)
  - Residents of long-term care facilities
- **Outpatients with progressive illness**

**Timing:**
- **Greatest benefit within 48 hours** of symptom onset
- **Still treat if >48h** if hospitalized or high-risk (benefit persists)
- **Don't wait for testing** if high suspicion + severe illness

## Key Points

### **Oseltamivir Dosing Adjustments:**
- **Renal impairment (CrCl <60):** Dose reduction required
  - CrCl 30-60: 30mg PO BID
  - CrCl 10-30: 30mg PO daily
  - ESRD: 30mg after each HD session
- **Severe illness (ICU):** Consider **double-dose oseltamivir 150mg PO BID** (controversial, some experts recommend)

### **Resistance:**
- **Oseltamivir resistance:** Rare (<2%), mostly in immunocompromised
- **Adamantanes (amantadine, rimantadine):** NO LONGER RECOMMENDED (>99% resistance)

### **Chemoprophylaxis:**
- **Post-exposure prophylaxis:** Oseltamivir 75mg PO daily × 10 days (or zanamivir)
- **Indications:** High-risk exposed contacts, unvaccinated healthcare workers during outbreak
- **NOT a substitute for vaccination**

### **Secondary Bacterial Pneumonia:**
- **Common:** *S. aureus* (including MRSA), *S. pneumoniae*, *H. influenzae*, GAS
- **Suspect if:** Fever recurs after improvement, hypoxia worsens, new infiltrate
- **Empiric:** Vancomycin + ceftriaxone (or pip-tazo)

### **Clinical Pearls:**
- **Oseltamivir 75mg PO BID × 5 days** (first-line)
- **Treat within 48h** (greatest benefit), but **still treat >48h if severe/high-risk**
- **Don't wait for testing** if severe illness (treat empirically)
- **PCR gold standard** (rapid antigen low sensitivity)
- **Baloxavir:** Single-dose alternative (newer, more expensive)
- **Secondary bacterial pneumonia** common (*S. aureus*, *S. pneumoniae*)

## Sources

- [CDC: Influenza Antiviral Guidelines 2024]
- [IDSA: Influenza Treatment 2023]

## Media

N/A
